TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04190719

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multimodal prehabilitation
Description: Paprika prehabilitation program content: patients will have choices for each activity. Messages and motivation will be reinforced by using a mobile app or leaflet advices, according to patient's preferences.~* Physical activity promotion by discovering ebike, personalised gymnastics and encouragement to increase the number of daily steps of patients, measured by a wristband and a mobile App~* An individualized nutritional optimization plan with dietary advices and protein supplementation (if necessary).~* Psychological support will be proposed through auto-hypnosis sensibilisation or management of stress with Cognitive Behavior Stress Management technics
Study: NCT02889471

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERCP with NB
Description: ERCP with NB catheter for introperative tans-nasobiliary cholangiography

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP alone
Description: ERCP alone followed with standard laparoscopic cholecystectomy
Study: NCT02620644

Intervention type: DEVICE
Group type: OTHER
Intervention: OCT Retinal GCC
Description: measuring of the retinal ganglion cell complex (GCC) thickness and the central foveal thickness (CFT) using the RTVue® SD-OCT (Optovue, Inc.)

Intervention type: DEVICE
Group type: OTHER
Intervention: OCT Retinal GCC
Description: measuring of the retinal ganglion cell complex (GCC) thickness and the central foveal thickness (CFT) using the RTVue® SD-OCT (Optovue, Inc.)
Study: NCT02171494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVAX Warfarin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS Coumadin
Study: NCT00810576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Dose of 200 mg by mouth twice daily on days 1-14 of each 21-day study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Dose of 1.3 mg/m\^2 by vein on days 1, 4, 8, and 11 of a 21 day cycle.
Study: NCT01771471

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NuQu
Description: Allogenic juvenile chondrocytes (NuQu) in fibrin carrier.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: 0.9% w/v Sodium Chloride for Injection, USP
Study: NCT02879357

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: 1. Clinician training~2. System for patient selection~3. System of triggering and tracking conversations~4. Training on how to use the Serious Illness Care Guide, a guide for patients about initiating conversations with family members about end-of-life goals and values~5. Longitudinal Medical Record (LMR) documentation module to serve as a Single source of truth about advance care preferences in the LMR.
Study: NCT00378404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 30 mg/m2 IV on days 1, 8, 15 every 28 days for 6 cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 50 - 80 cGy on days 1, 8, 15 every 28 days for 6 cycles
Study: NCT04086836

Intervention type: DEVICE
Intervention: TAVR
Description: Patient recieving a TAVR
Study: NCT04041349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mouse nerve growth factor
Description: mouse nerve growth factor of 20 UG (9000 U)/day for 14 consecutive days by intramuscular injection
Study: NCT02711683

Intervention type: DRUG
Intervention: DL-3-n-butylphthalide
Description: the patients with mild to moderate AD have already been prescribed the drugs,we just observed passively.

Intervention type: DRUG
Intervention: Donepezil
Description: the patients with mild to moderate AD have already been prescribed the drugs,we just observed passively.

Intervention type: DRUG
Intervention: Donepezil
Description: the patients with mild to moderate AD have already been prescribed the drugs,we just observed passively.
Study: NCT02344719

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taurin 6g per day per oral for 28 days
Description: Taurin 6g per day per oral for 28 days

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HVPG Measurement baseline
Description: On day 1 (baseline) and day 28 HVPG measurement will be performed

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: HVPG Measurement baseline
Description: On day 1 (baseline) and day 28 HVPG measurement will be performed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HVPG Measurement day 28
Description: On day 1 (baseline) and day 28 HVPG measurement will be performed

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: HVPG Measurement day 28
Description: On day 1 (baseline) and day 28 HVPG measurement will be performed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 6g per day per oral for 28 days
Description: Placebo to Taurin 6g per day per oral for 28 days
Study: NCT03632863

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Patient Decision Aid
Description: The electronic PDA is an interactive website with 3 main sections:~1. Review of depression treatment options (non-pharmacological and pharmacological) along with their respective risks and benefits.~2. Interactive values clarification exercises to help women determine which risks and benefits are most important to them.~3. Exercises to help women consider how partners, family, providers and the social context impacts decision-making.~A summary of how a woman feels about each option along with risks and benefits is generated which can be provided to treating clinicians for use in follow-up.~A printable pdf with standard published information and resources is also included.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Resource Sheet
Description: A control group aims to isolate the PDA's effects from time and clinical care. Controls login to the study website and receive the same printable pdf as in the PDA so that they can access standard publicly available information/resources, even if they will not receive the PDA.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Standard Resource Sheet
Description: A control group aims to isolate the PDA's effects from time and clinical care. Controls login to the study website and receive the same printable pdf as in the PDA so that they can access standard publicly available information/resources, even if they will not receive the PDA.
Study: NCT02767895

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Participants will receive an informational DVD, a pedometer, an incentive spirometer and access to the program website to help promote healthful behaviors and improved well-being in the days leading up to surgery.
Study: NCT06048432

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy + telephysiotherapty
Description: Patients assigned to the telephyisiotherapy (TP) group will carry out a half-hour session of conventional therapy, plus a 1-hour session of physical exercise, which will be carried out through the administration of tutorial videos, telephone instructions or by email.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy + telephysiotherapty
Description: Patients assigned to the telephyisiotherapy (TP) group will carry out a half-hour session of conventional therapy, plus a 1-hour session of physical exercise, which will be carried out through the administration of tutorial videos, telephone instructions or by email.
Study: NCT00278889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2171
Description: oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: intravenous infusion
Study: NCT04353765

Intervention type: DRUG
Intervention: Cabozantinib monotherapy
Description: Intervention description (FDA Label): kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma (RCC).

Intervention type: DRUG
Intervention: All authorized TKI monotherapies in advanced RCC per FDA label in advanced RCC
Description: As per authorized FDA label in advanced RCC
Study: NCT04549714

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High AI in paroxysmal atrial fibrillation
Description: Patients with paroxysmal AF will receive pulmonary vein vestibule ablation with high AI value, the AI target value for the front wall and the top wall is 550, and the rear wall and the lower wall are 400.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Middle AI in paroxysmal atrial fibrillation
Description: Patients with paroxysmal AF will receive pulmonary vein vestibule ablation with middle AI value, the AI target value for the front wall and the top wall is 500, and the rear wall and the lower wall are 350.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low AI in paroxysmal atrial fibrillation
Description: Patients with paroxysmal AF will receive pulmonary vein vestibule ablation with low AI value, the AI target value for the front wall and the top wall is 450, and the rear wall and the lower wall are 300.
Study: NCT06050473

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve-sacrificing procedure
Description: Surgical fixation of the clavicle fracture will be performed through a horizontal incision over the clavicle. During the incision and soft tissue dissection, the surgeon will not attempt to identify the supraclavicular nerve branches. Instead, the surgeon will cut the nerve branches during the dissection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve preserving procedure
Description: Surgical fixation of the clavicle fracture will be performed through the same horizontal incision over the clavicle. The surgeon will attempt to dissect out, identify and preserve all branches of the supraclavicular nerve throughout the fracture reduction, fixation and closure.
Study: NCT04193449

Intervention type: DIAGNOSTIC_TEST
Intervention: colonoscopy
Description: colonoscopy procedure
Study: NCT01861691

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open surgery
Description: Conventional technique
Study: NCT04324099

Intervention type: OTHER
Intervention: Reactive Proactive Questionnaire (RPQ) (for children)
Description: The Reactive-Proactive Questionnaire (RPQ) scores (0 (never), 1 sometimes, 2 (often)) for proactive aggression items and reactive items. Proactive and reactive scale scores are summated to obtain total aggression scores.
Study: NCT03986827

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cool Kids Anxiety Program - Social Enhanced
Description: Specific G-CBT intervention for adolescents with social anxiety disorder

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cool Kids Anxiety Program
Description: Generic G-CBT intervention for adolescents with anxiety disorders
Study: NCT01850186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual yellow Laser
Description: Patients will receive treatment by stabilized kilnman trio for four weeks (one application per day). Patient will receive 4 treatments by Dual yellow Laser on the hemi-face (side determinated by randomisation, split body study) at weeks 4, 6, 9 and 12.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Stabilized kilnman trio
Description: The stabilized kilnman trio will be prescribed for one month at inclusion (all over the face, one application per day), and on the half of the face not treated by laser at weeks 4, 8 and 12 (one application per day).
Study: NCT01963286

Intervention type: DEVICE
Group type: OTHER
Intervention: ICD with enhanced SVT discriminators
Description: ICD will be programmed to uniform device settings with enhanced SVT discrimintators enabled.
Study: NCT04308226

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: The navigator's principal role is to guide participants through the lung cancer screening (LCS) process. The navigator will work within the existing Boston Health Care for the Homeless (BHCHP) clinical structure and collaborate with participants' primary care providers (PCPs) to facilitate LCS low-dose computed tomography (LDCT) referral, completion, and timely follow-up by addressing participants' barriers to LCS completion and enhancing participants' self-efficacy. The navigator's secondary role is to offer brief tobacco counseling for participants who currently smoke.
Study: NCT03141866

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention 1: Move It Or Lose It (MIOLI)
Description: An established chair-based physical activity programme for older adults.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention 2: Machine-based resistance training intervention
Description: Specialised, chair-based, pneumatic resistance training equipment for older adults.
Study: NCT01772758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BH4 5mg
Description: Kuvan® or sapropterin dihydrochloride is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4). Subjects received an oral dose of 5 mg/kg of Kuvan® (Biomarin Pharmaceuticals Inc.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BH4 20mg
Description: Kuvan® or sapropterin dihydrochloride is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4). Subjects received an oral dose of 20 mg/kg of Kuvan® (Biomarin Pharmaceuticals Inc.)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidant Cocktail
Description: Vitamin C (1000 mg) , Vitamin E (600 IU) , and alpha-lipoic acid (600 mg). all BID
Study: NCT03587389

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix vaccine
Description: In this study, the 1st dose of Rotarix vaccine will be administered when infants are at ages between weeks 8-9 and the 2nd dose is 28-37 days after the 1st dose, which means that there is an interval of 28-37 days or 4-5 weeks between doses. A reminding call will be set at about 4 weeks after the 1st dose to remind parents to bring their children back to Hung Vuong Hospital for the 2nd dose of Rotarix to ensure the completion of the 2nd dose of Rotarix vaccine.
Study: NCT02636543

Intervention type: OTHER
Intervention: Questionnaire after the reading of letter B.
Description: Oral questionnaire after the reading of letter B.

Intervention type: OTHER
Intervention: Questionnaire after the reading of letter B.
Description: Oral questionnaire after the reading of letter B.

Intervention type: OTHER
Intervention: Questionnaire after the reading of letter B.
Description: Oral questionnaire after the reading of letter B.

Intervention type: OTHER
Intervention: Questionnaire after the reading of letter B.
Description: Oral questionnaire after the reading of letter B.

Intervention type: OTHER
Intervention: Questionnaire after the reading of letter B.
Description: Oral questionnaire after the reading of letter B.

Intervention type: OTHER
Intervention: Questionnaire after the reading of letters A and B
Description: Oral questionnaire after the reading of letters A and B during individual interview.

Intervention type: OTHER
Intervention: Questionnaire after the reading of letters A and B
Description: Oral questionnaire after the reading of letters A and B during individual interview.

Intervention type: OTHER
Intervention: Questionnaire after the reading of letters A and B
Description: Oral questionnaire after the reading of letters A and B during individual interview.
Study: NCT01861691

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Description: New minimum invasive technique
Study: NCT04324099

Intervention type: OTHER
Intervention: Reactive Proactive Questionnaire (RPQ) (for children)
Description: The Reactive-Proactive Questionnaire (RPQ) scores (0 (never), 1 sometimes, 2 (often)) for proactive aggression items and reactive items. Proactive and reactive scale scores are summated to obtain total aggression scores.

Intervention type: OTHER
Intervention: Emotion Regulation Questionnaire (for children)
Description: 10-item scale designed to measure respondents' tendency to regulate their emotions in two ways: (1) Cognitive Reappraisal and (2) Expressive Suppression. Respondents answer each item on a 7-point Likert-type scale ranging from 1 (strongly disagree) to 7 (strongly agree)

Intervention type: OTHER
Intervention: Emotion Regulation Questionnaire (for children)
Description: 10-item scale designed to measure respondents' tendency to regulate their emotions in two ways: (1) Cognitive Reappraisal and (2) Expressive Suppression. Respondents answer each item on a 7-point Likert-type scale ranging from 1 (strongly disagree) to 7 (strongly agree)
Study: NCT04602910

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a web-based shared decision-making tool
Description: Five major parts were developed with the use of the action research approach. The Introduction and Options (parts 1 and 2) describe the severity of the cancer treatment and infertility and the knowledge of fertility preservation, respectively. The SDM tool was designed as a step by step process (part 3) that involves the comparison of options, patient's values and preferences, their knowledge regarding infertility and options, and reaching a collective decision. The Resources (part 4) provide information on the hospitals that provide such services, and the References (part 5) list all the literature cited in the website. The results show the web-based SDM meets both the patients' and health providers' needs and helps reproductive-age patients with breast cancer make decisions on fertility preservation.
Study: NCT04006223

Intervention type: DIAGNOSTIC_TEST
Intervention: 11C-PIB or 18F-florbetapir PET/MR before biopsy and treatment
Description: 10-20 mCi 11C-PIB or 5-10 mCi 18F-florbetapir will be injected intravenously prior to imaging.
Study: NCT03278795

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pressure support ventilation mode
Description: PSV is the sole mode of mechanical ventilation and will be used as a weaning mode in mechanically ventilated chronic obstructive pulmonary disease patients,In PSV weaning group , PS(pressure support) will be adjusted at 8 cmH2O until 2-h successful spontaneous breathing trial parameters according to ERS(European Respiratory Society) guidelines will be achieved and then patient will ex-tubated.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: volume support ventilation mode
Description: VSV mode could be viewed as PRVC for spontaneous breathing as it delivers a variable pressure to meet a target VT. VSV will be used as a weaning mode in mechanically ventilated chronic obstructive pulmonary disease patients,In VSV weaning group ,VT(tidal volume ) will be adjusted at 6 ml/ Kg until 2-h successful spontaneous breathing trial parameters according to ERS guidelines will be achieved and then patient will ex-tubated.
Study: NCT04490213

Intervention type: OTHER
Intervention: Allevyn, Aquacel and Tegaderm, Mediskin
Description: Wound dressing tested earlier on donor sites, in this study scar outcome between the 3 dressing groups are compared.

Intervention type: OTHER
Intervention: Allevyn, Aquacel and Tegaderm, Mediskin
Description: Wound dressing tested earlier on donor sites, in this study scar outcome between the 3 dressing groups are compared.

Intervention type: OTHER
Intervention: Allevyn, Aquacel and Tegaderm, Mediskin
Description: Wound dressing tested earlier on donor sites, in this study scar outcome between the 3 dressing groups are compared.
Study: NCT03763812

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endovascular Aneurysm Repair (EVAR)
Description: The following blood samples will be taken: WBC and circulating cytokines (TNF-α, Interleukin (IL)-1, 1RA, 6, 10, 18, CRP), Troponin T, HsTnT, NT-pro-BNP at these time points:~* Before induction of anesthesia~* At wound closure~* 24 hours after surgery~* 48 hours after surgery~* 1 month after surgery~* 6 months after surgery~* 12 months after surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endovascular Aneurysm Sealing (EVAS)
Description: The following blood samples will be taken: WBC and circulating cytokines (TNF-α, Interleukin (IL)-1, 1RA, 6, 10, 18, CRP), Troponin T, HsTnT, NT-pro-BNP at these time points:~* Before induction of anesthesia~* At wound closure~* 24 hours after surgery~* 48 hours after surgery~* 1 month after surgery~* 6 months after surgery~* 12 months after surgery
Study: NCT01360424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Daily administration of teriparatide 20 ug s.c. for 24 months
Study: NCT00817323

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dietary amino-acid depletion
Description: See detailed description
Study: NCT01959178

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LD127025 MF
Description: At Visit 1, one-half of the subjects will be randomized to receive the investigational soft contact lens, after approximately one week of wearing the first lens type, the subjects will return for the 1-Week Crossover Visit (Visit 2) for an exam, and to determine if the subject remains eligible to continue in the next phase of the study with the control soft contact lens.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LD127025 MF
Description: At Visit 1, one-half of the subjects will be randomized to receive the investigational soft contact lens, after approximately one week of wearing the first lens type, the subjects will return for the 1-Week Crossover Visit (Visit 2) for an exam, and to determine if the subject remains eligible to continue in the next phase of the study with the control soft contact lens.
Study: NCT04006223

Intervention type: DIAGNOSTIC_TEST
Intervention: 11C-PIB or 18F-florbetapir PET/MR after treatment
Description: 10-20 mCi 11C-PIB or 5-10 mCi 18F-florbetapir will be injected intravenously prior to imaging.
Study: NCT03565458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin
Description: zemiglo 50mg,LG Chem

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin
Description: zemiglo 50mg,LG Chem

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin
Description: zemiglo 50mg,LG Chem

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: forxiga, dapagliflozin 10mg